Successful Completion of Pre-clinical Safety Studies With MIV-818, Enabling Start of Phase I Clinical Studies in 2018

January 7, 2018

Responsive image

STOCKHOLM, Jan. 8, 2018 /PRNewswire/ —
Medivir AB (Nasdaq Stockholm: MVIR) today announced the successful completion of the pre-clinical safety studies for MIV-818 to enable the start of phase I clinical trials in 2018.
MIV-818 is Medivir’s proprietary liver-targeted nucleotide…

Category: Precious Metals